Enantioselective synthesis and teratogenicity of propylisopropyl acetamide, a CNS-active chiral amide analogue of valproic acid

Chirality

Volumn 11, Issue 8, 1999, Pages 645-650

  Spiegelstein, Ofer ^c   Bialer, Meir ^c   Radatz, Matthias ^a   Nau, Heinz ^a   Yagen, Boris ^b  

^a UNIVERSITY OF VETERINARY MEDICINE HANNOVER   (Germany)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^c NONE

Author keywords

Antiepileptic drugs; Isopropyl triflate; Oxazolidinone chiral auxiliaries

Indexed keywords

2 ISOPROPYLVALERAMIDE; VALNOCTAMIDE; VALPROIC ACID; VALPROMIDE;

ARTICLE; CHIRALITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENANTIOMER; GAS CHROMATOGRAPHY; PRIORITY JOURNAL; STEREOCHEMISTRY; TERATOGENICITY; TOXICITY TESTING;

ABNORMALITIES, DRUG-INDUCED; ALLYLISOPROPYLACETAMIDE; ANIMALS; ANTICONVULSANTS; FEMALE; MALE; MICE; PREGNANCY; STEREOISOMERISM;

EID: 0032832441     PISSN: 08990042     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1520-636X(1999)11:8<645::AID-CHIR6>3.0.CO;2-7     Document Type: Article

References (30)

1. Bourgeois BFD. Valproic acid: Clinical use. In: Levy RH, Mattson RH, Meldrum BS, editors. Antiepileptic Drugs, 4th edition. New York: Raven Press; 1995; pp 633-639.
2. Bialer M. Clinical pharmacology of valpromide. Clin Pharmacokinet 1991;20:114-122.
3. Bialer M, Haj-Yehia A, Badir K, Hadad S. Can we develop improved derivatives of valproic acid? Pharm World Sci. 1994;16:2-6.
4. Nau H, Loscher W. Pharmacologic evaluation of various metabolites and analogs of valproic acid. Fund Appl Toxicol 1986;6:669-676.
5. Haj-Yehia A, Bialer M. Structure-pharmacokinetic relationships in a series of valpromide derivatives with antiepileptic activity. Pharm Res 1989;6:683-689.
6. Kaneko S, Kondo T. Antiepileptic agents and birth defect: Incidence, mechanisms and prevention. CNS Drugs 1995;3:41-55.
7. Robert E, Guibaud P. Maternal valproic acid and congenital neural tube defects. Lancet 1982;2:937.
8. Lindhout D, Meinardi H, Meijer JWA, Nau H. Antiepileptic drugs and teratogenesis in two consecutive cohorts: Changes in prescription policy paralleled by changes in pattern of malformations. Neurology 1992;42(Suppl. 5):94-110.
9. Lammer EJ, Seven LE, Oakley GPJ. Teratogen update: Valproic acid. Teratology 1987;35:465-473.
10. Nau H, Hendrickx AG. Valproic acid teratogenesis. ISI Atlas Sci: Pharmacol 1987;1:52-56.
11. Radatz M, Ehlers K, Yagen B, Bialer M, Nau H. Valnoctamide, valpromide and valnoctic acid are much less teratogenic in mice than valproic acid. Epilepsy Res 1998;30:41-48.
12. Nau H, Hauck RS, Ehlers K. Valproic acid induced neural tube deffects in mouse and human: aspects of chirality, alternative drug development, pharmacokinetics and possible mechanisms. Pharmacol Toxicol 1991;69:310-321.
13. Hauck RS, Nau H. Asymmetric synthesis and enantioselective teratogenicity of 2-n-propyl-4-pentenoic acid (4-en-VPA), an active metabolite of the anticonvulsant drug, valproic acid. Toxicol Lett 1989;49:41-48.
14. Hauck RS, Nau H. The enantiomers of the valproic acid analogue 2-H-propyl4-pentynoic acid (4-yn-VPA): Asymmetric synthesis and highly stereoselective teratogenicity in mice. Pharm Res 1992;9:850-855.
15. Takeo K, Kazuhiko U, Hisayȯshi M. Derivatives of α-cyclodextrin and the synthesis of 6-o-α-D-glucopyranosyl-α-cyclodextrin. J Carbohydr Chem 1988;7:293-308.
16. Dietrich A, Maas B, Messer W, Bruche G, Karl V, Kaunzinger A, Mosandl A. Stereoisomeric flavor compounds, part 58: The use of heptakis (2,3-di-o-methyl-6-o-tert-butyldimethylsilyl)-β-cyclodextrin as a chiral stationary phase in flavor analysis. J High Res Chromatogr 1992; 15:590-593.
17. Evans DA, Ennis MD, Mathre DJ. Asymmetric alkylation reactions of chiral imide etiolates. J Am Chem Soc 1982;104:1737-1739.
18. Evans DA Studies in asymmetric synthesis, the development of practical chiral enolate synthons. Aldrichim Acta 1982;15:23-32.
19. Stang PJ, Hanack M, Subramanian LR. Perfluoroalkanesulfonic esters: Methods of preparation and applications in organic chemistry. Synthesis 1982;39:85-125.
20. Evans DA, Britton TC, Ellman JA. Contrasteric carboximide hydrolysis with lithium hydroperoxide. Tetrahedron Lett 1987;28:6141-6144.
21. Nau H, Scot WJJ. Weak acids may act as teratogens by accumulating in the basic milieu of the early mammalian embryo. Nature 1986;323: 276-278.
22. Ariens EJ. Nonchiral, homochiral and composite chiral drugs. Chirality 1993;14:68-75.
23. Caldwell J. The importance of stereochemistry in drug action and disposition. J Clin Pharmacol 1992;32:925-929.
24. Hurt AJ, Tan SC. Drug chirality and its clinical significance. Drugs 1996;52(suppl 5):1-12.
25. Bialer M, Rubinstein A Raz I, Abramsky O. Pharmacokinetics of valpromide after oral administration of a solution and a tablet to healthy volunteers. Eur J Clin Pharmacol 1984;27:501-503.
26. Bialer M, Rubinstein A Dubrovsky J, Raz I, Abramsky O. A comparative pharmacokinetic study of valpromide and valproic acid after intravenous administration in humans. Int J Pharm 1985;23:25-33.
27. Bialer M, Rubinstein A A comparative study on the pharmacokinetics of valpromide after intravenous administration to dogs. J Pharm Pharmacol 1983;35:607-609.
28. Bialer M, Rubinstein A Pharmacokinetics of valpromide in dogs after various modes of administration. Biopharm Drug Dispos 1984;5:177-183.
29. Blotnik S, Bergman F, Bialer M. Disposition of valpromide, valproic acid, and valnoctamide in the brain, liver, plasma, and urine of rats. Drug Metab Disposit 1996;24:560-564.
30. Bojic U, Elmazar MM, Hauck RS, Nau H. Further branching of valproate-related carboxylic acids reduces the teratogenic activity, but not the anticonvulsant effect. Chem Res Toxicol 1996;9:866-870.